All In Biotech

Drug Trial Radar · NCT04408820

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Specified Drug Use-Results Survey of EVRENZO® Tablets: Non-interventional, Prospective Drug Use-results Survey in the Realworld Use of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,104

Actual

Start

Jun 1, 2020

Primary completion

Jun 23, 2025

Study completion Jun 23, 2025

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
May 29, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy, including the incidence of thromboembolism, in renal anemia patients treated with roxadustat (EVRENZO® Tablets) in actual clinical settings.

Conditions

  • Renal Anemia

Interventions

  • RoxadustatDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Adverse Drug Reactions (ADR)Time frame: Up to Week 104
  2. Proportion of participants with serious ADRTime frame: Up to Week 104
  3. Proportion of participants with thromboembolismTime frame: Up to Week 104
  4. Proportion of participants with hypertensionTime frame: Up to Week 104
  5. Proportion of participants with hepatic function disorderTime frame: Up to Week 104
  6. Proportion of participants with malignant tumorsTime frame: Up to Week 104
  7. Proportion of participants with retinal hemorrhageTime frame: Up to Week 104
  8. Proportion of Participants With SeizuresTime frame: Up to week 104
  9. Proportion of Participants With Serious InfectionTime frame: Up to week 104
  10. Proportion of Participants With Central HypothyroidsmTime frame: Up to Week 104
  11. Proportion of participants with myopathy eventsTime frame: Up to Week 104
  12. Proportion of Participants With Renal Function DisorderTime frame: Up to week 104
  13. Proportion of participants with ADR within 4 weeks after switching to roxadustatTime frame: Up to Week 4
  14. Proportion of participants with ADR with high doses of roxadustatTime frame: Up to Week 104
  15. Change from baseline in Hemoglobin (Hb) levelsTime frame: Up to Week 104
  16. Mean value of Hb levels over timeTime frame: Up to Week 104
  17. Achievement rate for target Hb levelTime frame: Up to Week 104
  18. Mean Hb levels at 4 weeks after switching to roxadustatTime frame: At Week 4

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • Site JP00023

    Aichi, Japan

  • Site JP00005

    Akita, Japan

  • Site JP00002

    Aomori, Japan

  • Site JP00012

    Chiba, Japan

  • Site JP00038

    Ehime, Japan

  • Site JP00018

    Fukui, Japan

  • Site JP00040

    Fukuoka, Japan

  • Site JP00007

    Fukushima, Japan

  • Site JP00021

    Gifu, Japan

  • Site JP00010

    Gunma, Japan

  • Site JP00034

    Hiroshima, Japan

  • Site JP00001

    Hokkaido, Japan

  • Site JP00028

    Hyōgo, Japan

  • Site JP00008

    Ibaraki, Japan

  • Site JP00017

    Ishikawa, Japan

  • Site JP00037

    Kagawa, Japan

  • Site JP00046

    Kagoshima, Japan

  • Site JP00014

    Kanagawa, Japan

  • Site JP00039

    Kochi, Japan

  • Site JP00043

    Kumamoto, Japan

  • Site JP00026

    Kyoto, Japan

  • Site JP00024

    Mie, Japan

  • Site JP00004

    Miyagi, Japan

  • Site JP00045

    Miyazaki, Japan

  • Site JP00020

    Nagano, Japan

  • Site JP00042

    Nagasaki, Japan

  • Site JP00029

    Nara, Japan

  • Site JP00015

    Niigata, Japan

  • Site JP00003

    Numakunai, Japan

  • Site JP00044

    Ōita, Japan

  • Site JP00033

    Okayama, Japan

  • Site JP00047

    Okinawa, Japan

  • Site JP00027

    Osaka, Japan

  • Site JP00041

    Saga, Japan

  • Site JP00011

    Saitama, Japan

  • Site JP00025

    Shiga, Japan

  • Site JP00032

    Shimane, Japan

  • Site JP00022

    Shizuoka, Japan

  • Site JP00009

    Tochigi, Japan

  • Site JP00036

    Tokushima, Japan

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.